AB
$4.18
-0.15
(-3.46%)
As of Oct 22, 2026, 9:18 AM EDT
Price history
Arbutus Biopharma Corp (ABUS) is trading down at $4.18 (-3.46%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Arbutus Biopharma Corp revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.49M | $10.7M | $5.95M | $6.01M | $6.91M | $11.0M | $39.0M | $18.1M | $6.17M | $14.1M |
| Growth (year over year) | −93.6% | +617.6% | −44.4% | +1.1% | +15.0% | +58.9% | +255.1% | −53.5% | −66.0% | +128.2% |
| Operating income | −$491.6M | −$110.9M | −$89.8M | −$143.9M | −$57.8M | −$73.5M | −$65.5M | −$78.1M | −$76.3M | −$38.2M |
| Operating margin | −32973.8% | −1036.7% | −1510.2% | −2394.0% | −836.1% | −669.1% | −167.8% | −430.5% | −1236.7% | −271.0% |
| Net income | −$384.2M | −$84.4M | −$57.1M | −$153.7M | −$63.7M | −$76.2M | −$69.5M | −$72.8M | −$69.9M | −$33.5M |
| Net margin | −25765.5% | −788.9% | −959.8% | −2557.4% | −922.0% | −693.9% | −178.0% | −401.6% | −1133.0% | −237.9% |
| EPS (diluted) | −$7.24 | −$1.56 | −$1.21 | −$2.89 | −$1.00 | −$0.83 | −$0.46 | −$0.44 | −$0.38 | −$0.17 |
| Balance sheet | ||||||||||
| Cash and equivalents | $23.4M | $54.3M | $36.9M | $31.8M | $52.3M | $109.3M | $30.8M | $26.3M | $36.3M | $18.0M |
| Total assets | $275.9M | $237.2M | $227.9M | $105.5M | $137.1M | $204.5M | $195.4M | $144.4M | $131.7M | $94.6M |
| Total liabilities | $72.9M | $54.7M | $27.7M | $32.8M | $35.1M | $35.0M | $58.6M | $38.4M | $34.3M | $18.0M |
| Long-term debt | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Shareholders' equity | $203.0M | $182.5M | $200.2M | $72.7M | $102.0M | $169.4M | $136.9M | $106.0M | $97.4M | $76.6M |
| Cash flow | ||||||||||
| Operating cash flow | −$57.9M | −$48.6M | −$67.9M | −$71.0M | −$51.4M | −$67.5M | −$35.4M | −$85.9M | −$64.8M | −$39.6M |
| Capital expenditure | $4.00M | $7.26M | $1.14M | $589.0K | $229.0K | $809.0K | $512.0K | $1.01M | $182.0K | $0 |
| Free cash flow | −$61.9M | −$55.9M | −$69.0M | −$71.6M | −$51.7M | −$68.3M | −$35.9M | −$86.9M | −$65.0M | −$39.6M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.34M | $1.57M | $1.76M | $10.7M | $529.0K | — | $179.1M | $1.01M |
| Growth (year over year) | −71.3% | −26.6% | +15.1% | +522.2% | −60.5% | — | +10054.5% | −90.6% |
| Operating income | −$21.4M | −$13.9M | −$25.7M | $1.49M | −$8.66M | — | $168.9M | −$5.96M |
| Operating margin | −1601.2% | −885.2% | −1456.9% | 13.9% | −1636.9% | — | 94.3% | −588.2% |
| Net income | −$19.7M | −$12.5M | −$24.5M | $2.52M | −$7.74M | — | $169.7M | −$5.14M |
| Net margin | −1472.5% | −796.2% | −1390.4% | 23.5% | −1463.5% | — | 94.7% | −507.2% |
| EPS (diluted) | −$0.10 | −$0.07 | −$0.13 | $0.01 | −$0.04 | — | $0.87 | −$0.03 |
| Balance sheet | ||||||||
| Cash and equivalents | $31.8M | $36.3M | $37.1M | $37.4M | $22.4M | $18.0M | $23.7M | $19.2M |
| Total assets | $140.4M | $131.7M | $117.0M | $103.3M | $97.7M | $94.6M | $277.2M | $274.0M |
| Total liabilities | $33.6M | $34.3M | $37.9M | $20.3M | $20.3M | $18.0M | $17.0M | $15.3M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Shareholders' equity | $106.9M | $97.4M | $79.2M | $83.0M | $77.4M | $76.6M | $260.2M | $258.7M |
| Cash flow | ||||||||
| Operating cash flow | −$20.7M | −$10.3M | −$13.4M | −$15.7M | −$5.82M | — | −$8.11M | −$6.02M |
| Capital expenditure | $0 | $86.0K | $0 | $0 | $0 | — | — | — |
| Free cash flow | −$20.7M | −$10.4M | −$13.4M | −$15.7M | −$5.82M | — | — | — |
From Arbutus Biopharma Corp's 10-K, 10-Q and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Arbutus Biopharma Corp
- Headquarters
- Warminster, Pennsylvania From SEC filings, Oct 2026
Recent News (2)
-
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease…
-
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International